SCHEMBL98623

SCHEMBL98623

C1CCSOC1.[Sn]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240128 0.97
SCHEMBL5426968 0.97
SCHEMBL5438594 0.97
SCHEMBL8841873 0.97
SCHEMBL1071786 0.93
SCHEMBL8842231 0.93
SCHEMBL525562 0.93
SCHEMBL347410 0.93
SCHEMBL5686296 0.93
SCHEMBL204465 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364222-A1 RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS DEVACELL, INC. 2023-11-16 US claimed
WO-2022076756-A1 RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS DEVACELL, INC. (US) 2022-04-14 WO claimed
US-20240026305-A1 RECOMBINANT ONCOLYTIC VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS DEVACELL, INC. 2024-01-25 US disclosed
US-20230364222-A1 RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS DEVACELL, INC. 2023-11-16 US disclosed
WO-2022109503-A1 RECOMBINANT ONCOLYTIC VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS DEVACELL, INC. (US) 2022-05-27 WO disclosed
WO-2022076756-A1 RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS DEVACELL, INC. (US) 2022-04-14 WO disclosed
US-9958446-B2 Method for treatment of blood tumor using anti-TIM-3 antibody KYOWA HAKKO KIRIN CO., LTD (JP) 2018-05-01 US disclosed
US-9540441-B2 Polynucleotide encoding antibody to human IL-3 receptor alpha chain KYOWA HAKKO KIRIN CO., LTD (JP) 2017-01-10 US disclosed
US-20160363595-A1 METHOD FOR TREATMENT OF BLOOD TUMOR USING ANTI-TIM-3 ANTIBODY KYOWA HAKKO KIRIN CO., LTD (JP) 2016-12-15 US disclosed
US-9487591-B2 Method for treatment of blood tumor using anti-TIM-3 antibody KYOWA HAKKO KIRIN CO., LTD (JP) 2016-11-08 US disclosed
US-20160280792-A1 ANTIBODY TO HUMAN IL-3 RECEPTOR ALPHA CHAIN KYOWA HAKKO KIRIN CO., LTD (JP) 2016-09-29 US disclosed
US-9103832-B2 Method for treatment of blood tumor using anti-TIM-3 antibody KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-08-11 US disclosed
EP-2426148-B1 ANTI-IL-3RA ANTIBODY FOR USE IN TREATMENT OF BLOOD TUMOR KYOWA HAKKO KIRIN CO LTD (JP) 2015-08-05 EP disclosed
US-20140134639-A1 METHOD FOR TREATMENT OF BLOOD TUMOR USING ANTI-TIM-3 ANTIBODY KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2014-05-15 US disclosed
US-20130295107-A1 ANTIBODY TO HUMAN IL-3 RECEPTOR ALPHA CHAIN KYOWA KIRIN CO., LTD. (JP) 2013-11-07 US disclosed
US-8492119-B2 Antibody to human IL-3 receptor alpha chain KYOWA HAKKO KIRIN CO., LTD (JP) 2013-07-23 US disclosed
US-8480662-B2 Systems and devices for photoablation CARDIAC PACEMAKERS, INC. (US) 2013-07-09 US disclosed
US-20120070448-A1 ANTI-IL-3RA ANTIBODY FOR USE IN TREATMENT OF BLOOD TUMOR KYOWA HAKKO KIRIN CO., LTD (JP) 2012-03-22 US disclosed
EP-2426148-A1 ANTI-IL-3RA ANTIBODY FOR USE IN TREATMENT OF BLOOD TUMOR Kyowa Hakko Kirin Co., Ltd. (JP) 2012-03-07 EP disclosed
EP-2417984-A1 METHOD FOR TREATMENT OF BLOOD TUMOR USING ANTI-TIM-3 ANTIBODY Kyowa Hakko Kirin Co., Ltd. (JP) 2012-02-15 EP disclosed